Aspirin in Transient Ischemic Attacks "AITIA"


Phase N/A Results

Trial Description

To determine whether aspirin has a clinical benefit in the prevention of arterial thromboembolism and its consequences.


Trial Design

Double-blind, placebo-controlled, multicenter trial of 303 patients at 10 centers.

Patient Involvement

Assignment into the medical and surgical groups was made by the responsible physician based on the patients' baseline clinical and laboratory evaluation. Each group was then independently randomized (after surgery in the surgical group). Patients randomized to aspirin received 650 mg twice daily. Blinded follow-up evaluations were done at 4-week intervals during the first 6 months following hospital discharge and every 3 months thereafter through 24 months. At each follow-up visit, the patient was interviewed and examined by a neurologist and blood, urine, and stool tests were performed.


Type Measure Time Frame Safety Issue
Primary Overall mortality, stroke-related mortality, retinal infarction, nonfatal cerebral infarction.
Secondary TIAs pre- and post-randomization.


National Heart, Lung, and Blood Institute, NIH